Lansoprazole (CAS 103577-45-3)

Lansoprazole is a proton pump inhibitor (PPI) that exerts its action by selectively and irreversibly binding to the H+/K+-ATPase enzyme system located on the secretory surface of gastric parietal cells. This binding leads to a significant reduction in the secretion of gastric acid by these cells, effectively lowering stomach acidity. The mechanism involves the inhibition of the final step in the acid production process, thereby preventing the generation of hydrochloric acid. In research applications, lansoprazole has been widely utilized as a tool to study the regulation of gastric acid secretion, the pathophysiology of gastroesophageal reflux disease (GERD), and other acid-related disorders. Its role extends to investigating the gastroprotective mechanisms, including the effects on mucosal defense and the modulation of pepsin secretion. Lansoprazole′s ability to profoundly suppress acid secretion makes it an invaluable compound in experimental models focusing on the healing and prevention of injury to the gastric mucosa caused by excessive acid exposure. Through these models, insights into the underlying mechanisms of acid-related diseases and the potential protective roles of acid suppression can be gained, contributing to the broader understanding of gastrointestinal physiology. Lansoprazole is more potent than omeprazole (sc-202265).